Scientific Research Publishing

American Journal of Analytical Chemistry, 2026, 17(3), 45-60
https://www.scirp.org/journal/ajac
ISSN Online: 2156-8278
ISSN Print: 2156-8251

Frameworks for the Future: Implementing FDA Guidance on Artificial Intelligence in Biopharma

Kishore Raju Vatsavai[1], Jayaram Kamma[2], Anil Kumar Ramgiri[3], Kishore Kumar Hotha[4*]

[1]Veranova, Devens, USA
[2]Lupin, Somerset, USA
[3]Appco Pharma LLC, New Jersey, USA
[4]Dr. Hotha's Life Sciences LLC, Ayer, USA
Email: *drhotha@drhothas.com

How to cite this paper: Vatsavai, K.R., Kamma, J., Ramgiri, A.K. and Hotha, K.K. (2026) Frameworks for the Future: Implementing FDA Guidance on Artificial Intelligence in Biopharma. *American Journal of Analytical Chemistry*, **17**, 45-60.
https://doi.org/10.4236/ajac.2026.173005

Received: February 3, 2026
Accepted: March 27, 2026
Published: March 30, 2026

Abstract

Artificial Intelligence (AI) is transforming the pharmaceutical industry, from early drug discovery to post-market surveillance. The recent Food and Drug Administration (FDA) draft guidance "Artificial Intelligence in Drug and Biological Product Development"—outlines regulatory expectations for AI/ML in drug development, emphasizing transparency, reliability, and human oversight. This article compiles insights from regulatory discussions, technical literature, and real-world applications to examine how AI speeds up innovation while introducing new challenges. It highlights key opportunities in R&D, clinical development, manufacturing, and quality assurance, and discusses the future path for pharma and biotech organizations striving to responsibly incorporate AI into their operations.

Keywords

Artificial intelligence (AI), Machine Learning (ML), Drug Development, FDA Guidance, Biopharmaceutical Regulation, Clinical Trials, Pharmaceutical Manufacturing, Pharmacovigilance

1. Introduction: Demystifying AI's Regulatory Role in Drug Development

Artificial Intelligence (AI) is no longer just a futuristic addition to drug development—it's quickly becoming a central force in how we discover, evaluate, and deliver therapies [1]-[3]. From modeling protein-ligand interactions to automating quality control in manufacturing, AI and Machine Learning (ML) systems are al-

ready integrated throughout pharmaceutical R&D and commercial operations [2] [3]. However, the regulatory oversight of AI is not uniform across all these applications, and understanding where regulatory expectations apply is critical.

The U.S. Food and Drug Administration (FDA) draft guidance on *Artificial Intelligence in Drug and Biological Product Development*, released in 2023, addresses this need by clarifying regulatory expectations specifically for AI systems that support regulatory-relevant decisions [4] (**Figure 1**). While AI is widely used in early discovery and internal research, the draft guidance is primarily concerned with AI tools whose outputs influence regulated activities such as nonclinical and clinical study design, manufacturing and quality decisions, or data submitted in support of investigational or marketing applications. Exploratory or internal AI applications used solely for hypothesis generation or discovery generally fall outside the scope of the guidance unless their outputs are used to inform regulatory submissions or decision-making.



Figure 1. What is included and excluded under the FDA draft guidance for AI in drug development.

The guidance signals how the FDA expects sponsors to document, validate, and manage AI-based tools used in regulated contexts, emphasizing transparency, reliability, risk-based validation, and appropriate human oversight. Importantly, it does not impose new legal requirements [4] [5]; rather, it provides a framework for aligning innovative AI methodologies with existing scientific and regulatory principles [6].

Viewed in the context of the FDA's broader regulatory evolution from the 21st Century Cures Act to expanded use of real-world evidence (RWE) and digital health the draft guidance reflects a deeper shift in regulatory thinking [6]. The agency is preparing to evaluate algorithm-driven tools in much the same way it has historically evaluated assays, analytical methods, and manufacturing controls, focusing on intended use, risk, and lifecycle management [6] [7].

This article examines the FDA's draft guidance through that lens, distinguishing between AI used broadly across the drug development lifecycle and AI that directly supports regulatory-relevant decisions. Drawing on regulatory discussions, technical literature, and real-world examples, it explores implications for regulatory strategy, AI validation, and lifecycle management across therapeutic

areas such as oncology, cell and gene therapy, and complex biologics [1] [8].

2. Understanding the FDA's Draft Guidance on AI in Drug and Biological Product Development

The FDA's *Draft Guidance for Industry: Considerations for the Use of Artificial Intelligence in Drug and Biological Product Development* (2023) is a pivotal document aimed at demystifying the regulatory expectations around AI/ML tools [4]. It's designed not to stifle innovation, but to ensure clarity, consistency, and trust in AI-based methodologies used throughout the drug lifecycle.

2.1. Scope and Relevance of the FDA Draft Guidance

This draft guidance focuses on how artificial intelligence and machine learning technologies are being applied in the development of drugs and biological products. Its primary intent is to set expectations and offer clarity for sponsors who plan to integrate AI tools across the lifecycle of drug development—from early research to regulatory submission and beyond.

Importantly, this document is not applicable to AI-based software used as medical devices, which fall under separate regulatory frameworks. Instead, the guidance speaks directly to AI tools used for:

- *Designing and conducting clinical trials*.
- *Interpreting nonclinical data*.
- *Enhancing manufacturing and product quality* (*Chemistry, Manufacturing, and Controls* (*CMC*) *applications*).
- *Leveraging real-world data and pharmacovigilance*.

The guidance does not impose new legal requirements but serves as a framework to align AI use with existing scientific and regulatory principles. By offering this direction, the FDA encourages early communication and proactive planning with regulators, helping ensure that AI-driven methods are trustworthy, scientifically justified, and aligned with public health goals [4] [5].

2.2. Key Regulatory Themes and Expectations for AI Use in Drug Development

The FDA's draft guidance outlines several foundational themes that are essential when integrating AI/ML into drug and biological product development. At its core, the document emphasizes transparency, reliability, and proactive planning as critical pillars of responsible AI adoption [7] [8].

2.2.1. Transparency in AI Models

Transparency doesn't just mean explaining the model's function—it also includes how the model was trained, the nature and origin of the data, its limitations, and any bias that may be embedded in its performance [9] [10]. Regulatory submissions involving AI should clearly describe:

- *The purpose and scope of the AI tool*.
- *The development process, including datasets used for training and validation*.

- *Measures taken to ensure data integrity and generalizability.*

This level of openness allows regulatory reviewers to evaluate the scientific validity of the tool [4] [9] and its appropriateness for its intended use.

2.2.2. Risk-Based Thinking

The guidance advocates for a **risk-based approach** to AI deployment. Sponsors are expected to assess the impact of AI tools on product quality, patient safety, and decision-making. For instance, if an AI tool influences dosing decisions or trial endpoints, the regulatory bar will be higher compared to tools used for internal resource planning or supply chain modeling [11] [12] (**Figure 2** and **Figure 3**).

Risk assessments should consider:

- *The degree of automation versus human oversight.*
- *The potential for AI-related errors to affect clinical outcomes.*
- *The strategies in place for monitoring AI performance over time.*

RISK MATRIX FOR AI MODELS

Decision Consequence vs. Model Influence

DECISION CONSEQUENCE	MODEL INFLUENCE	RISK LEVEL
Low	Low	Low Risk
Low	High	Medium Risk
High	Low	Medium Risk
High	High	High Risk

Figure 2. Risk Matrix for artificial intelligence models used in regulatory decision-making.



Figure 3. Stepwise framework for risk-based credibility assessment of AI models.

2.2.3. Lifecycle Management and Updates

AI models are not static; they often evolve as new data becomes available. The FDA stresses the importance of **managing AI tools over their lifecycle**—including plans for periodic retraining, performance re-validation, and documentation of updates. This is especially critical in the context of continuous learning systems, where model drift can pose hidden risks [11] [13].

Regulators expect sponsors to outline:

- How changes to the model will be controlled and documented.
- What version control mechanisms exist.
- How post-deployment monitoring will be conducted, particularly in real-world use scenarios.

2.2.4. Early and Ongoing Engagement

Finally, the FDA encourages early communication between sponsors and regulatory agencies. Engaging with the FDA through pre-submission meetings or INTERACT meetings allows for alignment on expectations, especially when novel AI applications are being proposed [4].

This open dialogue helps avoid surprises late in the development process and fosters a shared understanding of how AI tools will support regulatory decisions.

3. Applications of AI across the Drug Development Lifecycle

Artificial intelligence is reshaping nearly every phase of drug and biologics development—from discovery to post-market surveillance (**Figure 4**). Its utility stems not only from the ability to accelerate tasks traditionally performed by humans, but also from uncovering patterns and insights that are otherwise imperceptible. The FDA's draft guidance recognizes this cross-cutting potential, outlining how AI can support regulatory decision-making when used responsibly and transparently [4] [14].



Figure 4. Examples of artificial intelligence applications across the drug development lifecycle.

3.1. Preclinical Discovery and Early-Stage Development

In the discovery phase, AI algorithms are being used to model protein-ligand in-

teractions, screen virtual compound libraries, and predict off-target effects. Deep learning models, especially graph neural networks and transformer-based architectures, are enabling faster lead identification with improved accuracy [1] [3]. Moreover, natural language processing (NLP) tools can mine vast datasets—from biomedical literature to patents—to identify novel therapeutic targets or repurpose existing drugs.

In early development, AI is also leveraged for high-content screening, automating image analysis in cell-based assays, and optimizing synthetic pathways.

An AI model is used to integrate in vitro assay data and in vivo toxicology results to predict a safe starting dose for first-in-human studies. The AI output supports selection of the maximum recommended starting dose (MRSD) included in an IND submission. Because this model directly informs human dosing decisions, its performance, training data, and limitations would be subject to FDA scrutiny under a risk-based framework [4] [15].

3.2. Clinical Trial Design and Execution

AI supports clinical trial design in several transformative ways:

- **Patient recruitment and stratification**: Machine learning models can mine electronic health records (EHRs) and genomic data to identify eligible patients and stratify them into appropriate trial arms [8].
- **Synthetic control arms**: In rare diseases or high-risk indications, AI-generated synthetic control arms—based on historical data—may reduce the need for placebo groups, although this approach still requires rigorous validation [15].
- **Trial monitoring and adaptive protocols**: AI can analyze real-time data to flag protocol deviations or recommend adaptive changes to dosing or inclusion criteria.

The FDA guidance encourages early engagement if AI will influence key trial decisions, especially if the tool is tied to primary endpoints or safety assessments.

An AI-based algorithm is used to stratify patients and recommend adaptive modifications to enrollment criteria based on interim efficacy and safety data during a Phase II clinical trial. The model's outputs inform protocol amendments and influence interpretation of primary endpoints submitted to the FDA. Given its direct impact on trial conduct and regulatory conclusions, this use case represents a high-risk application requiring robust validation, transparency, and defined human oversight [4] [15].

3.3. Manufacturing and Quality Control

AI/ML tools have growing utility in **process development**, **process control, and manufacturing operations**. Examples include:

- **Multivariate process monitoring**: AI can detect subtle shifts in critical process parameters before they result in deviations or out-of-specification batches.
- **Predictive maintenance**: ML-based predictive maintenance systems reduce downtime by anticipating equipment failures.
- **Release testing automation**: Computer vision and machine learning are also

enhancing the speed and objectivity of visual inspections, dissolution profile assessments, and impurity tracking [16]-[18].

An AI model is deployed to evaluate multivariate process data and determine whether a drug product batch meets predefined quality specifications for release. The AI output supports batch disposition decisions documented in regulatory submissions. Because erroneous outputs could directly affect product quality and patient safety, this application carries high regulatory risk and must meet validation and lifecycle management expectations equivalent to conventional release testing methods.

The FDA guidance stresses that if AI tools are used to release or reject product batches, they must meet the same validation and reliability expectations as conventional methods [4] [18] [19].

3.4. Regulatory Submissions and Decision Support

AI can assist sponsors in compiling submission-ready documentation, such as electronic Common Technical Document (eCTD) modules, by organizing large volumes of data, identifying inconsistencies, and suggesting summaries. In addition, NLP can help regulators navigate previous precedent, advisory committee minutes, and similar product reviews.

However, the FDA remains cautious about fully automating regulatory decisions. The guidance clarifies that AI tools used to inform regulatory pathways or submissions must be well-documented and not replace human expert judgment [4].

3.5. Post-Market Surveillance and Real-World Evidence

Post-approval, AI systems are being applied to analyze real-world data for pharmacovigilance. By processing EHRs, insurance claims, and social media signals, AI can detect adverse event signals faster and more sensitively than manual methods [6] [20] [21].

An AI-based signal detection system is used to analyze real-world data and identify potential safety signals that trigger expedited adverse event reporting and labeling updates. The AI output supports regulatory safety reporting obligations and post-marketing risk management decisions. As these outputs may prompt regulatory action, the model's data sources, performance characteristics, and bias controls are subject to regulatory evaluation.

AI is also key to evaluating **real-world effectiveness**, as it enables the integration of heterogeneous data sources to assess how therapies perform across broader patient populations [20] [21].

4. Challenges, Risks, and FDA Considerations in Deploying AI in Drug Development

Despite the transformative potential of artificial intelligence, its integration into regulated pharmaceutical processes introduces a complex set of challenges (**Figure 5**). These span scientific, technical, regulatory, and ethical dimensions. The

FDA's draft guidance on the use of AI in drug and biological product development serves as a timely framework to address these complexities while encouraging innovation.

4.1. Transparency and Explainability

One of the most significant hurdles is the "black-box" nature of many AI models—particularly deep learning approaches. While these models may demonstrate high performance, they often lack interpretability. This opacity can hinder scientific understanding, undermine trust, and complicate regulatory evaluations [9] [10].

FDA emphasizes that sponsors should ensure their AI models are accompanied by documentation that explains how they were developed, trained, validated, and how they operate. This includes a clear rationale for the model's architecture, input data, and any preprocessing steps. Tools that inform regulatory decisions must allow for meaningful interpretation and justification of their outputs [4] (**Figure 5** and **Figure 6**).



Figure 5. Regulatory and technical challenges in the use of AI for drug development.



Figure 6. FDA-Led initiatives and cross-sector collaborations supporting the use of artificial intelligence in drug development.

4.2. Data Integrity and Bias

AI models are only as reliable as the data they are trained on. If datasets are incomplete, unbalanced, or poorly curated, the resulting models can perpetuate or even amplify biases. This has implications for patient safety, especially when AI is used for patient selection, dose prediction, or safety signal detection.

The FDA draft guidance calls for transparency regarding data sources, preprocessing, and handling of missing data. Sponsors are expected to assess and mitigate potential sources of bias, and to justify the representativeness of their training and testing data, especially in diverse populations [10] [21] [22].

Across nonclinical, clinical, manufacturing, and post-market contexts, regulatory risk is driven not by the presence of AI itself, but by the specific decision being supported and its potential impact on patient safety, product quality, or regulatory outcomes [4].

4.3. Validation and Lifecycle Management

Unlike traditional software, AI models can evolve over time—particularly when adaptive learning or real-time updating is involved. This raises critical questions about version control, reproducibility, and change management.

FDA urges sponsors to follow a total product lifecycle approach for AI tools. This includes rigorous model validation using independent test datasets, stress-testing across use cases, and a post-deployment monitoring plan. If a model will evolve over time (e.g., through continued learning), predefined protocols must be in place to manage such updates without compromising regulatory compliance [4] [11] [12].

For AI tools that support regulatory-relevant decisions or data included in INDs, NDAs, or BLAs, sponsors should assemble a **credibility/validation package** addressing the following minimum elements:

4.3.1. Data Provenance and Suitability

- Clear description of data sources, collection context, and preprocessing steps.
- Justification of data relevance to the intended use (population, process, or setting).
- Assessment of data completeness, representativeness, and potential bias.

4.3.2. Training, Validation, and Testing Strategy

- Description of data partitioning (training/validation/test splits).
- Use of independent test sets; external validation where feasible.
- Rationale when external validation is not possible.

4.3.3. Performance Metrics and Acceptance Criteria

- Pre-specified performance metrics aligned with the regulatory context of use.
- Quantitative acceptance criteria defined before model evaluation.
- Comparison to baseline or conventional methods, where applicable.

4.3.4. Failure-Mode and Limitation Analysis

- Identification of known failure modes and conditions where performance degrades.
- Sensitivity analyses for edge cases or out-of-distribution inputs.
- Risk mitigation strategies and defined role of human oversight when failures occur.

This package should be maintained within the sponsor's quality system and referenced in regulatory submissions to support transparency, reproducibility, and confidence in AI-supported conclusion.

To operationalize a total product lifecycle approach, sponsors should manage AI models using established change-control principles. AI models used to support regulatory-relevant decisions should be versioned and traceable to training data and intended use. Sponsors should predefine triggers for model updates, including performance drift or changes in data or use conditions, and conduct risk-appropriate revalidation to demonstrate continued fitness for use. Documentation of model changes and performance monitoring should be maintained within the quality system. FDA interaction is generally appropriate when changes affect intended use or regulatory conclusions.

4.4. Human Oversight and Decision Accountability

AI tools can support—but not replace—human expertise in regulatory decision-making. Even when models demonstrate high accuracy, final decisions must rest with qualified professionals who understand the AI tool's context and limitations.

To ensure clear decision accountability in regulated environments, sponsors should define minimum human-oversight controls for AI-assisted activities. Each AI tool used to support regulatory-relevant decisions should have a named accountable role (e.g., study lead, manufacturing quality lead, or safety physician) responsible for approving use, interpreting outputs, and authorizing final decisions.

AI-assisted decisions should be supported by review and audit trails documenting the model version used, input data, outputs generated, and the human rationale for accepting or rejecting those outputs. When AI outputs conflict with expert judgment or predefined expectations, escalation pathways should be defined, including secondary expert review and documentation of resolution prior to regulatory submission or operational action.

Human-oversight practices should be embedded within existing standard operating procedures (SOPs) and quality systems to ensure consistency with established governance, training, deviation management, and inspection readiness expectations. These controls reinforce that AI outputs serve as decision support rather than autonomous decision-makers

The guidance is explicit: AI outputs used in regulatory submissions should be viewed as supportive evidence, not sole arbiters [4] [23]. Sponsors must define the role of human judgment in interpreting and acting on AI-driven insights.

4.5. Cybersecurity and Data Privacy

AI tools often require access to sensitive clinical, genomic, or manufacturing data. Ensuring the security and confidentiality of these datasets is essential—especially when models are hosted in cloud environments or integrated across multiple systems.

Sponsors must demonstrate that appropriate safeguards are in place for data storage, access, and transmission. Additionally, privacy-preserving techniques such as federated learning or differential privacy may be explored when handling patient-level data [24] [25].

4.6. Regulatory Engagement and Submission Readiness

Finally, integrating AI into drug development processes will likely require early and frequent interaction with regulatory authorities. The FDA encourages sponsors to engage through existing pathways such as pre-Investigational New Drug (IND) meetings, Type C meetings, or the Innovation and Science Technology Approaches for New Drugs (ISTAND) pilot program when proposing novel methodologies.

Documentation must clearly state the AI tool's intended use, performance metrics, limitations, and any associated risk controls. Submissions should include technical files (e.g., source code summaries, version histories) and scientific justification for how AI outputs support the drug's safety, efficacy, or quality [4].

5. Future Outlook and Evolving Regulatory Paradigms

The intersection of artificial intelligence and pharmaceutical development is rapidly advancing, and regulatory frameworks must evolve in parallel to maintain both scientific rigor and public trust. The FDA's recent draft guidance is not a fixed endpoint but rather a foundational step toward adaptive, lifecycle-based regulation of AI in drug development [4] (**Figure 7**).



Figure 7. Key takeaways for the responsible implementation of artificial intelligence in drug development.

5.1. Shifting from Static to Adaptive Regulation

Traditional regulatory frameworks were built around fixed, well-characterized processes. AI, by contrast, is dynamic. Models may evolve through continuous learning, retraining, or integration of real-world evidence. This demands a more adaptive regulatory model—one that recognizes and supports controlled evolution over time without compromising quality or safety.

Regulators are exploring approaches such as predetermined change control plans (PCCPs), model updates within defined limits, and real-time monitoring. These mechanisms can allow innovation to proceed while keeping oversight tight where it matters most.

5.2. Cross-Disciplinary Collaboration

As AI becomes integral to the drug development value chain—from preclinical modeling to manufacturing analytics—future success will hinge on deep collaboration between pharmaceutical scientists, data scientists, regulatory experts, and clinicians. No single discipline can navigate these complexities alone.

This will also require upskilling the workforce across both industry and regulatory agencies. Regulatory scientists will need fluency in AI methods, while developers must build systems with compliance, explainability, and risk control in mind from day one [8].

5.3. Standardization and Global Alignment

Inconsistent expectations across global regulators can slow down innovation and create duplication of effort. Initiatives like the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) work on digital technologies and FDA's collaboration with international health authorities signal a move toward harmonization.

As industry adoption grows, we may also see the emergence of shared AI validation frameworks, model cards, and documentation templates. These can reduce review burden, improve transparency, and set industry-wide expectations for responsible use.

5.4. Expanding AI's Reach across the Lifecycle

So far, much attention has focused on AI's use in early-phase discovery or limited clinical trial support. But its impact on manufacturing, supply chain optimization, pharmacovigilance, and post-market surveillance is only beginning to unfold.

FDA has signaled openness to AI-enabled tools across all stages, provided that their role is clearly defined and their limitations understood. The future may include AI-driven process control in real-time release testing, or safety signal detection across massive real-world datasets. Each application will come with unique regulatory nuances that demand tailored solutions.

5.5. Building a Culture of Responsible Innovation

Ultimately, AI in pharma must serve patients. This means striking a balance between innovation and caution, speed and scrutiny. Ethical considerations—such as fairness, accountability, and data privacy—must be embedded in both technology and policy design.

Regulators like FDA are playing a critical role in shaping a culture of responsible innovation. Their guidance encourages early engagement, continuous learning, and transparent communication—principles that will underpin the next generation of digital transformation in healthcare [8] [26]-[29] (**Figure 8**).



Figure 8. Future vision for the responsible adoption of artificial intelligence in drug development.

6. Conclusions

Artificial intelligence is no longer a theoretical tool in the pharmaceutical industry—it's an active driver reshaping how drugs are discovered, developed, manufactured, and monitored. From early-stage molecule screening to real-time process control in manufacturing, AI's role is expanding rapidly. But innovation without clear governance risks undermining both patient safety and scientific credibility.

The FDA's draft guidance, *"Considerations for the Use of Artificial Intelligence in Drug and Biological Product Development"*, represents a crucial step in aligning regulatory oversight with the evolving technological landscape. Rather than prescribing rigid rules, the agency sets a tone of flexible, risk-based thinking. It encourages sponsors to proactively engage with regulators, define the intended use of AI tools, and ensure transparency, reproducibility, and ongoing oversight across the product lifecycle.

The path forward demands more than compliance. It calls for a cultural shift across pharma and biotech—toward cross-functional collaboration, robust documentation, and a commitment to responsible innovation. As both regulatory expectations and AI capabilities mature, companies that integrate ethical, scientific, and regulatory thinking from the outset will be best positioned to deliver trans-

formative therapies—safely, efficiently, and at scale [4].

This is the moment to build that foundation—before AI becomes too embedded to shape. The guidance is here. The tools are emerging. Now it's up to developers, regulators, and scientific leaders to rise to the occasion.

7. Disclosure

The views and opinions expressed are solely those of the authors in their individual capacities and do not represent, and should not be attributed to, any current or former employer, affiliated entity, client, or related organization of any author. No such organization participated in, reviewed, influenced, approved, endorsed, or funded this work. This article was prepared independently using only publicly available information and contains no proprietary, confidential, or non-public information of any organization. Nothing herein constitutes professional advice, creates any agency, partnership, or fiduciary relationship, or represents any organization in any capacity.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., *et al.* (2019) Applications of Machine Learning in Drug Discovery and Development. *Nature Reviews Drug Discovery*, **18**, 463-477. https://doi.org/10.1038/s41573-019-0024-5

[2] Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P. and Zhavoronkov, A. (2016) Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data. *Molecular Pharmaceutics*, **13**, 2524-2530. https://doi.org/10.1021/acs.molpharmaceut.6b00248

[3] Mak, K. and Pichika, M.R. (2019) Artificial Intelligence in Drug Development: Present Status and Future Prospects. *Drug Discovery Today*, **24**, 773-780. https://doi.org/10.1016/j.drudis.2018.11.014

[4] U.S. Food and Drug Administration (2023) Artificial Intelligence in Drug and Biological Product Development: Draft Guidance for Industry. https://www.regulations.gov/document/FDA-2023-N-0743-0001

[5] U.S. Food and Drug Administration (2024) Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products. Discussion Paper and Request for Feedback. https://www.fda.gov/media/167973/download

[6] U.S. Food and Drug Administration (2022) Real-World Evidence Program: Framework. https://www.fda.gov/media/120060/download

[7] U.S. Food and Drug Administration (2021) Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device Action Plan. https://www.fda.gov/media/145022/download

[8] Harrer, S., Shah, P., Antony, B. and Hu, J. (2025) Artificial Intelligence in Clinical Trials: Opportunities, Challenges, and Future Directions. *Drug Discovery Today*, **30**, Article ID: 103470.

[9] Amann, J., Blasimme, A., Vayena, E., Frey, D. and Madai, V.I. (2020) Explainability for Artificial Intelligence in Healthcare: A Multidisciplinary Perspective. *BMC Medical Informatics and Decision Making*, **20**, Article No. 310. https://doi.org/10.1186/s12911-020-01332-6

[10] Sculley, D., Holt, G., Golovin, D., Davydov, E., Phillips, T., Ebner, D., *et al*. (2015) Hidden Technical Debt in Machine Learning Systems. *Advances in Neural Information Processing Systems* 28: *Annual Conference on Neural Information Processing Systems* 2015, Montreal, 7-12 December 2015, 1-9.

[11] Lu, J., Liu, A., Dong, F., Gu, F., Gama, J. and Zhang, G. (2025) Learning under Concept Drift: A Review on Data Drift Detection and Adaptation in Machine Learning for Healthcare. *Journal of Biomedical Informatics*, **151**, Article ID: 104654.

[12] Sendak, M.P., Gao, M., Nichols, M., Lin, A., Balu, S. and Barbian, H. (2024) Machine Learning Operations (MLOps) in Healthcare: A Scoping Review of Post-Deployment Monitoring and Governance. *NPJ Digital Medicine*, **7**, Article No. 64.

[13] Rabanser, S., Günnemann, S. and Lipton, Z.C. (2024) Failing Loudly: An Empirical Study of Dataset Shift Detection in Real-World Healthcare Data. *Nature Communications*, **15**, Article No. 2314.

[14] Vamathevan, J., Dunham, I. and Ferran, E. (2024) Artificial Intelligence across the Pharmaceutical Product Lifecycle. *Computers in Biology and Medicine*, **169**, Article ID: 107684.

[15] Horne, B.D., Manzi, S. and Mentz, R.J. (2025) Artificial Intelligence for Clinical Trial Risk Assessment and Adaptive Trial Design: A Scoping Review. *NPJ Digital Medicine*, **8**, Article No. 112.

[16] Bhardwaj, A. and Wanjari, M.M. (2023) Integration of Artificial Intelligence in Pharmaceutical Manufacturing for Quality Control and Supply Chain Management. *International Journal of Pharmaceutical Sciences and Research*, **14**, 612-620.

[17] Baranwal, Y., Singh, R. and Ierapetritou, M. (2025) Machine Learning Applications in Pharmaceutical Manufacturing of Oral Solid Dosage Forms: A Review. *International Journal of Pharmaceutics*, **654**, Article ID: 123982.

[18] Brunner, R., Gasser, R. and Korakianiti, E. (2025) Regulatory Perspectives on Artificial Intelligence and Machine Learning in Pharmaceutical Manufacturing and Quality Systems. *Pharmaceutical Research*, **42**, 1-15.

[19] International Council for Harmonization (2022) ICH Q2(R2): Validation of Analytical Procedures. https://www.ich.org/page/quality-guidelines

[20] Pfohl, S.R., Daniels, J. and Shah, N.H. (2025) Fairness Drift: Monitoring Algorithmic Bias over Time in Clinical Machine Learning Systems. *Journal of the American Medical Informatics Association*, **32**, 845-854.

[21] Choudhury, A. and Asan, O. (2020) Role of Artificial Intelligence in Patient Safety Outcomes: Systematic Literature Review. *JMIR Medical Informatics*, **8**, e18599. https://doi.org/10.2196/18599

[22] Ghassemi, M., Naumann, T., Schulam, P., Beam, A.L., Chen, I.Y. and Ranganath, R. (2021) A Review of Challenges and Opportunities in Machine Learning for Health. *AMIA Summits on Translational Science Proceedings*, San Francisco, 8-12 March 2021, 191-200.

[23] Grote, T., Berens, P. and Jäger, A. (2025) The Responsibility Vacuum in Post-Deployment Monitoring of Medical AI Systems. *AI & Society*, **40**, 1-15.

[24] Collins, G.S., Dhiman, P., Andaur Navarro, C.L., *et al*. (2024) TRIPOD+AI Statement: Updated Reporting Guidance for Diagnostic and Prognostic Prediction Models That

Use Artificial Intelligence. *BMJ*, **385**, e078378.

[25] Liu, X., Glocker, B., McCradden, M.M., *et al*. (2025) Guidelines and Standards for Artificial Intelligence in Healthcare: A Systematic Review of Reporting, Validation, and Governance Frameworks. *JAMIA Open*, **8**, ooae155.

[26] European Medicines Agency (2023) Artificial Intelligence in the Medicinal Product Lifecycle. https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/artificial-intelligence?utm_source=chatgpt.com

[27] International Council for Harmonization (2023) ICH Q13: Continuous Manufacturing of Drug Substances and Drug Products. https://www.ich.org/page/quality-guidelines

[28] Organization for Economic Co-operation and Development (2019) OECD Principles on Artificial Intelligence. https://oecd.ai/en/ai-principles

[29] Topol, E.J. (2019) High-Performance Medicine: The Convergence of Human and Artificial Intelligence. *Nature Medicine*, **25**, 44-56. https://doi.org/10.1038/s41591-018-0300-7